ArticleLupus science & medicine2026
Clinical value of simultaneous detection of anti-dsDNA and anti-chromatin antibodies using a multiplex immunoassay in systemic lupus erythematosus: a 5-year retrospective study.
Article in Lupus science & medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Advances and pitfalls in anti-double-stranded DNA autoantibody detection and interpretation.World journal of biological chemistry · 2026Review
- Affinity Peptide-Based Circularly Permuted Fluorescent Protein Biosensors Loaded in a Microfluidic System for Systemic Lupus Erythematosus Diagnosis.Sensors (Basel, Switzerland) · 2026Article
- Combined assessment of 25(OH)D, CD4Frontiers in immunology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo assess the clinical relevance of concurrent measurement of anti-chromatin antibodies and anti-double-stranded DNA (anti-dsDNA) antibodies using a multiplex immunoassay in systemic lupus erythematosus (SLE), focusing on their association with organ-specific manifestations and disease activity.
methodsAdult patients diagnosed with SLE based on the 2012 Systemic Lupus International Collaborating Clinics or 2019 European Alliance of Associations for Rheumatology/American College of Rheumatology criteria and followed in our university hospital between 2015 and 2019 were retrospectively included if they had at least one positive detection of anti-dsDNA and/or anti-chromatin result by a multiplex immunoassay, with clinical data available within the 30 days before or after testing. Clinical manifestations, treatments, laboratory parameters and disease activity (SLE Disease Activity Index 2000 (SLEDAI-2K)) were compared using mixed models and correlation coefficients.
results98 patients (88% women; median age 42 (IQR: 35-50)) had 677 antibody evaluations. Levels of anti-dsDNA and anti-chromatin antibodies were correlated (r=0.39, 95% CI 0.21 to 0.55). Results were discordant in 59 patients (60%), representing 215 assessments (32%), with anti-chromatin antibodies being detected without anti-dsDNA in 111/677 samples (16%). Rise in anti-dsDNA antibody titre was associated with cutaneous (OR 2.29, 95% CI 1.43 to 3.68) and musculoskeletal involvement (OR 1.29, 95% CI 1.02 to 1.64), while anti-chromatin antibody increase was linked to neuropsychiatric manifestations (OR 1.54, 95% CI 1.03 to 2.29). The increase of either antibody titre was independently associated with proteinuria >0.5 g/24 hours (anti-dsDNA antibody: OR 1.17, 95% CI 1.11 to 2.74; anti-chromatin antibody: OR 1.71, 95% CI 1.02 to 2.87). Correlation with SLEDAI-2K was moderate for anti-dsDNA (r=0.55; 95% CI 0.39 to 0.67), and weaker for anti-chromatin (r=0.32; 95% CI 0.16 to 0.51]).
conclusionsConcomitant measurement of anti-dsDNA and anti-chromatin antibodies using a multiplex immunoassay system brings complementary information for diagnosis and monitoring of SLE. Both antibodies are associated with disease activity and renal involvement, while anti-chromatin antibodies are associated with neuropsychiatric flares. Anti-chromatin antibodies provide additional diagnostic value, particularly in the absence of anti-dsDNA positivity that was observed in 16% of our cohort.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.